Craig Coleman
Professor/Pharmacy Practice
Storrs Mansfield
Are you Craig Coleman?
How to update your information.
Scholarly Contributions
620 Scholarly Contributions
Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis.
2021
Research Type: Journal Article
Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study.
2021
Research Type: Journal Article
Murad MH,... Coleman C, et al. Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence. J Clin Epidemiol. 2021 Jul;135:170-175. doi: 10.1016/j.jclinepi.2021.02.028. Epub 2021 Mar 19. PMID: 33753229.
2021
Research Type: Journal Article
Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
2021
Research Type: Journal Article
Improving the utility of evidence synthesis for decision makers in the face of insufficient evidence
2021
Research Type: Journal Article
Improving the Utility of Evidence Synthesis for Decision Makers in the Face of Insufficient Evidence [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Apr. Report No.: 21-EHC007. PMID: 33905185.
2021
Research Type: Other Scholarly Work
Ophthalmic Complications in Patients with Nonvalvular Atrial Fibrillation and Type 2 Diabetes Prescribed Rivaroxaban or Warfarin
2021
Research Type: Poster/Presentation
Stroke, Systemic Embolism, Vascular Death and Bleeding in Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes Receiving Rivaroxaban or Warfarin
2021
Research Type: Poster/Presentation
Ophthalmic complications in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin.
2021
Research Type: Poster/Presentation
Thromboembolism, bleeding, and vascular death among older and younger nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
2021
Research Type: Poster/Presentation
Characterizing safety and efficacy in ovarian cancer patients with thromboembolism treated with rivaroxaban.
2021
Research Type: Poster/Presentation
Interview with the expert: RIVA-DM – What do recent data tell us?
2021
Research Type: Poster/Presentation
Kidney, limb and ophthalmic complications and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: An electronic health record analysis.
2021
Research Type: Poster/Presentation
Patient characteristics and temporal changes in anticoagulation treatment patterns in patients diagnosed with cancer-associated thrombosis: An oscar-us analysis.
2021
Research Type: Poster/Presentation
Kidney, Limb and Ophthalmic Complications and Death in Patients with Nonvalvular Atrial Fibrillation Prescribed Rivaroxaban or Warfarin: An Electronic Health Record Analysis
2021
Research Type: Poster/Presentation
Do differences in baseline clinical severity of ovarian cancer patients with thrombosis predict treatment with rivaroxaban versus low molecular-weight heparin?.
2021
Research Type: Poster/Presentation
Communication of Medication Nonmedical Switching Policies and Procedures by Insurance Companies: Results of an E-Survey.
2020
Research Type: Journal Article
Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
2020
Research Type: Journal Article